

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-11 (Cancelled).

Claim 12 (Previously Presented): A nutritional or pharmaceutical composition for the inhibition of pathogenic bacteria adhesion to mammalian cells, or for reducing or inhibiting the invasion and infection of mammalian cells by pathogenic bacteria, wherein the mammal cells invaded or infected are mammalian gut or intestinal epithelial cells, the composition comprising:  
a first compound comprising methyl alpha manno-oligosaccharides in an amount of about 0.5% to about 50% by total weight of the composition; and  
a second compound comprising proanthocyanidins.

Claim 13 (Previously Presented): The nutritional or pharmaceutical composition according to claim 12, wherein the composition further comprises partially hydrolysed guar gum.

Claims 14-15 (Cancelled).

Claim 16 (Previously Presented): A nutritional or pharmaceutical composition for the treatment of acute or chronic pathogenic bacteria-associated enteric disorders in a mammal, or for the treatment of pathogenic bacteria microflora proliferation in a mammal, the composition comprising:

a first compound comprising methyl alpha manno-oligosaccharides in an amount of about 0.5% to about 50% by total weight of the composition; and

a second compound comprising proanthocyanidins.

Claim 17 (Previously Presented): The nutritional or pharmaceutical composition according to claim 16, wherein said acute or chronic pathogenic bacteria-associated enteric disorders are selected from the group consisting of gastroenteritis, ulcerative colitis, diarrhoeal diseases, and combinations thereof.

Claim 18 (Previously Presented): A method for inhibiting pathogenic bacteria adhesion to mammalian cells or for reducing or inhibiting the invasion and infection of mammalian cells by pathogenic bacteria, the method comprising administering to a mammal a composition comprising: a first compound comprising methyl alpha manno-oligosaccharides, wherein said mammalian cells are those of the gut and intestinal mammalian cells, and wherein the composition comprises about 0.5% to about 50% of the first compound by total weight of the composition; and a second compound comprising proanthocyanidins.

Claim 19 (Previously Presented): A method of treating acute or chronic pathogenic bacteria-associated, enteric disorders in a mammal, said method comprising administering to said mammal a composition comprising: about 0.5% to about 50% of methyl alpha manno-oligosaccharides by total weight of the composition.

Claim 20 (Previously Presented): The method according to claim 19, wherein said enteric disorders are selected from the group consisting of gastroenteritis, ulcerative colitis, diarrhoeal diseases, and combinations thereof.

Claim 21 (Previously Presented): The method according to claim 19, wherein the composition further comprises a therapeutically effect amount of partially hydrolysed guar gum.

Claims 22-23 (Cancelled).

Claim 24 (Previously Presented): A nutritional or pharmaceutical composition comprising methyl alpha manno-oligosaccharides, wherein the composition comprises about 2.5% to about 10% of the methyl alpha manno-oligosaccharides by total weight of the composition.

Claim 25-26 (Cancelled).

Claim 27 (Cancelled).

Claim 28 (Previously Presented): A method for the manufacture of a nutritional or pharmaceutical composition for the inhibition of pathogenic bacteria adhesion to mammalian cells, or for reducing or inhibiting the invasion and infection of mammalian cells by pathogenic bacteria, the method comprising adding to the nutritional or pharmaceutical composition a first compound comprising methyl alpha manno-oligosaccharides, wherein the mammalian cells are mammalian gut or intestinal epithelial cells, wherein the composition comprises about 0.5% to about 50% of the first compound by total weight of the composition; and adding to the nutritional or pharmaceutical composition a second compound comprising proanthocyanidin.

Claim 29 (Previously Presented): A method for the manufacture of a nutritional or pharmaceutical composition for the treatment of acute or chronic pathogenic bacteria-associated enteric disorders in a mammal or for the treatment of pathogenic bacteria microflora proliferation in the mammal, the method comprising adding to the nutritional or pharmaceutical composition a first compound comprising methyl alpha manno-oligosaccharides, wherein the composition comprises about 0.5% to about 50% of the first compound by total weight of the composition; and adding to the nutritional or pharmaceutical composition a second compound comprising proanthocyanidins.

Claim 30 (Previously Presented): A method according to claim 29, wherein said enteric disorders are selected from the group consisting of gastroenteritis, ulcerative colitis, diarrhoeal diseases, and combinations thereof.

Claim 31 (Cancelled).